Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company now aims for single-digit growth and about a 10% total return, focusing on predictability rather than rapid expansion. The business is viewed as low risk due to recurring revenue, minimal acquisition disruption, and sector resilience.
FREELANDER 8 has started mass production at the Chery Jaguar Land Rover Changshu Manufacturing Base in China, a facility with over $3.1 billion invested, including $440 million for NEV upgrades. This plant combines British premium manufacturing with ...
Cardano (ADA) is showing strong recovery momentum, pushing toward the key $0.20 resistance level. Despite a recent minor pullback, ADA remains above its 20-day and 50-day moving averages, signaling ongoing bullish strength. The critical level to watc...
XRP price is under bearish pressure, testing the crucial $1 support level after failing to break above its 20-day and 50-day moving averages. The cryptocurrency trades below major moving averages, signaling a continued downtrend since June's sharp dr...
Lighter (LIT) has surged to a three-week high of $2.4, up 9.23% on strong daily trading volume growth of 53% to $49 million. A major whale investor has spent $9.1 million over two months to accumulate 3.91 million LIT, including a recent $1 million p...
Lido revealed a bug during the rollout of Staking Router v3 where an AccountingOracle error missed a 32 ETH validator deposit, causing an incorrect stETH rebase rate of 2.04% APR. This issue occurred during the upgrade from a per-validator reward sys...
